Altered dopaminergic function and negative symptoms in drug-free patients with schizophrenia. [123I]-iodobenzamide SPECT study.
M B Knable, M F Egan, A Heinz...
https://pubmed.ncbi.nlm.nih.gov/9519100Completed
All Genders
Healthy Volunteers
ID00001320
I-123 Iodobenzamide (IBZM) SPECT Studies of D2 Receptor Distribution and Function in Patients With Schizophrenia and Normal Volunteers
Led by National Institute of Mental Health (NIMH) · Updated on 2008-03-04
265
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Brain cells communicate with each other by releasing chemicals called neurotransmitters. In order for brain cells to transfer information, one cell will release a neurotransmitter that will be recognized by a receptor located on surface of another cell. One such neurotransmitter is dopamine. Abnormal dopamine transmission has been seen in patients with substance abuse and different neuropsychiatric disorders including schizophrenia. A radioactive drug called IZBM (I-123 iodobenzamide) can also bind to certain dopamine receptors. IZBM can be seen by Single Photon Emission Tomography (SPECT). Therefore, by using IZBM and SPECT scans, researchers can find and "map" the location of dopamine receptors in the brain. Patients participating in this study must also have been selected for other genetic studies being conducted at the NIMH. Patients with schizophrenia will be selected from a NIMH research study titled, "Neurobiological Investigation of Patients with Schizophrenia Spectrum Disorders and Their Siblings" (95-M-0150). Normal patient volunteers will be selected from another NIMH study titled, "Inpatient Evaluation of Neuropsychiatric Patients" (89-M-0160). All aspects of clinical care and genetic analysis of these patients will be covered in these studies, while information pertaining to IBZM SPECT scans will be covered in this study. This study will not directly benefit patients participating in it. However, information gathered may contribute to faster and more accurate diagnosis of schizophrenia and eventually better treatment for the disorder.
CONDITIONS
Official Title
Neuroimaging of Dopamine Metabolism in Normal and Psychiatric Patients
Who Can Participate
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
INCLUSION CRITERIA:
Patients with schizophrenia will be recruited exclusively from among inpatients who are participating in clinical studies of the Clinical Brain Disorders Branch of NIMH under NIH protocol #89-M-0160 (Egan 1999a) and for whom genetic data is already available.
Normal volunteers will be recruited exclusively from among individuals who have volunteered for studies under NIH protocol #95-M-0150 (Egan 1999b) as normal control subjects and for whom genetic data is already being analyzed.
EXCLUSION CRITERIA:
Pregnancy: All women of childbearing age must undergo a pregnancy test prior to injection or radioactive isotope. If the pregnancy test is positive or if the woman has reason to believe she might be pregnant, she will be excluded from this study.
Breastfeeding: Women who are breastfeeding will be excluded from this study to avoid unwarranted risk to their children.
Iodine sensitivity: Subjects with a prior reaction to iodine, iodine compounds, or shellfish will be excluded from this study. Also, subjects with a history of thyroid disease or dysfunction will be excluded from this study.
Substance abuse: Subjects with a history of recent substance abuse will be excluded from this study.
Metal objects in body: Subjects with metal objects in their bodies as specified in our MRI protocol (91-M-0124) will be excluded from this study.
INCLUSION CRITERIA FOR PATIENTS WITH SCHIZOPHRENIA:
Prior participation as a NIMH inpatient under NIH protocol #89-M-0160.
Schizophrenia diagnosis according to DSM-IV criteria.
EXCLUSION CRITERIA FOR PATIENTS WITH SCHIZOPHRENIA:
Coexistence of another mental illness at the time of the study. If the patient has experienced other mental illnesses in the past (e.g. a learning disability or major depression), then this should be judged to be fully recovered.
INCLUSION CRITERIA FOR NORMAL CONTROLS:
Prior participation as a normal volunteer under NIH protocol #95-M-0150.
No Axis I or Axis II diagnoses.
EXCLUSION CRITERIA FOR NORMAL CONTROLS:
Subjects with an Axis I or II disorder will be excluded.
Subjects with concomitant medical or neurological disorders which require ongoing medication, or which may affect the central nervous system will be excluded.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Trial Site Locations
Total: 1 location
1
National Institute of Mental Health (NIMH)
Bethesda, Maryland, United States, 20892
Status Unknown
Loading map...
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.
M B Knable, A Heinz, T Raedler...
https://pubmed.ncbi.nlm.nih.gov/9351491Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding.
S S Wolf, D W Jones, M B Knable...
https://pubmed.ncbi.nlm.nih.gov/8703056